Today’s Annals of Oncology and ESMO Open Concomitant publications are available online: www.annalsofoncology.org/concomitant @myesmo.bsky.social #ESMO25

The First Annals of Oncology and ESMO Open Concomitant publications are available online: www.annalsofoncology.org/concomitant @myesmo.bsky.social #ESMO25

Update from the #POSITIVE trial at #ESMO25 - 71-month follow-up showed no increase in recurrence among women who paused treatment to conceive, offering important reassurance for patients and clinicians 👏 🇮🇪 participated, with CTI as national sponsor and Prof Janice Walsh as NLI. #BreastCancer

Another fantastic @myesmo.bsky.social GI oncology podcast about #oligometastatic #gastric cancer is finally out! Please take a moment to 🎧 and share it with your team: soundcloud.com/esmo-podcast...

Controversies in upper GI oncology: the definition and management of oligometastatic gastroesophageal tumours

In this Controversies in upper GI oncology podcast, Angelica Petrillo, gastrointestinal oncologist of Ospedale del Mare, Naples, Italy, presents a discussion between Professor Hanneke van Laarhoven,

soundcloud.com

ESMO 50th Anniversary: Half a Century of Evidence-Based Cancer Care @myesmo.bsky.social oncodaily.com/societies/es... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMO

ESMO 50th Anniversary: Half a Century of Evidence-Based Can

ESMO 50th Anniversary was celebrated on June 27, 2025, marking a historic milestone in the evolution of global cancer care. Over five decades,

oncodaily.com

Updates from the ESMO Gastrointestinal Cancers Congress 2025 @myesmo.bsky.social oncodaily.com/insight/esmo... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMO #ESMOGI25 #GIOnc

Updates from the ESMO Gastrointestinal Cancers Congress 2025 - OncoDaily

Updates from the ESMO Gastrointestinal Cancers Congress 2025 / cancer, colorectal cancer, CRC, ESMO, ESMO Daily Reporter, ESMO Gastrointestinal Cancers, ESMO

oncodaily.com

🚨 ESMO’s New Global Guidelines for Molecular Tumor Boards (MTBs) 🧬💻 Published in Annals of Oncology, this comprehensive special article by the @myESMO Precision Oncology Working Group delivers international recommendations to standardize MTB structure, quality, and function in clinical practice.

New research in Annals of Oncology shows that a breath-based diagnostic tool—an “electronic nose”—is getting surprisingly close to clinical reality. #lungcancer

Sniffing Out Lung Cancer: Breath Analyzer Moves Closer to Clinical Use

So-called eNose achieves 80-90% performance level for lung cancer detection

medpagetoday.com

📢 New in Annals of Oncology: Final survival results from the #PENELOPEB trial: Palbociclib vs placebo in high-risk HR+/HER2- breast cancer after neoadjuvant chemo. Full paper: www.annalsofoncology.org/article/S092...

📢 Delighted to share a new publication in Annals of Oncology. PEACE III is the first major Phase III trial to combine an ARPI with radiopharmaceutical that showed statistical significance in meeting the primary endpoint.https://ow.ly/SH8K50W1Zct @silkegillessen.bsky.social

Lung cancer detection by electronic nose analysis of exhaled breath: a multi-center prospective external validation study, published in Annals of Oncology. 👉 Read it before your patients: bit.ly/43NzBfO

Potential solid tumor indications for MRD continue to pile up, including new cervical cancer data presented at ASCO and simultaneously published in Annals of Oncology.

ASCO Data on Personalis Assay Suggests Role for ctDNA MRD Testing in Cervical Cancer

precisionmedicineonline.com

👉 Asia Pacific’s oncology spotlight is on you. Submit your abstract for ESMO Asia 2025 by 12 August. Get published in Annals of Oncology and connect with top experts in Singapore, 5–7 December. Your research. Your impact. #ESMOAsia25 🔗 buff.ly/ycEGK9a

An exciting first day of the ESMO Sarcoma and Rare Cancers congress with the launch of ESMO Rare Cancers! Congratulations to the Editorial team on reaching this important milestone. The inaugural issue is online: www.esmorarecancers.org/current

Gutted not to be Geneva 🇨🇭 for #ESMOImmuno24 in person this year 🥹. If you are presenting your work at #ESMOImmuno24, and potentially looking for a home for your research work, please consider submitting to our ESMO IOTECH journal: 🔗 esmoiotech.org

📢👏👏👏👏👏THANKS TO REFEREES 2024: The Editor-in-Chief and Associate Editors of Annals of Oncology would like to extend their sincere appreciation to all those who have worked as referees for the journal. www.sciencedirect.com/science/arti... #ESMO

THANKS TO REFEREES 2024

sciencedirect.com

New Annals of Oncology article in press: The Efficacy and Safety of Mirvetuximab Soravtansine in FRα-Positive, Third-Line and Later, Recurrent Platinum-Sensitive Ovarian Cancer: The Single-Arm Phase 2 PICCOLO Trial www.sciencedirect.com/science/arti... #ESMO

📖 #AnnalsOfOncology #DYK Alongside Annals of Oncology, ESMO’s portfolio includes ESMO Open, Immuno-Oncology and Technology, ESMO Gastrointestinal Oncology, ESMO Real World Data and Digital Oncology & ESMO Rare Cancers to provide comprehensive insights across #Oncology 🔗 ow.ly/exiT50UgvZl

I'm delighted to announce that ESMO Rare Cancers is now open for submissions! For more information on our aims & scope, please have a look at the introductory Editorial by the Co-Editors-in-Chief #ESMO #Oncology www.esmorarecancers.org/article/S305...

📖 #AnnalsOfOncology #MilestonesMonday: In 2008 Annals_ of Oncology became the official journal of the Japanese Society of Medical Oncology expanding its global influence and matching the society’s global expansion. #ESMO 🔗 ow.ly/9LCT50U8U9f

📖 @Annals of Oncology marks 35 years with Prof. David Kerr, Editor-in-Chief (2000-2009). He reflects on the journal’s growth, challenges, and offers advice for emerging researchers. Read the full interview 🔗 ow.ly/Osug50UbMfe

👉 Watch Prof. Gietema, Dr. Trama, Dr. Valverde & Prof. Girard discuss how collaboration drives better outcomes for rare cancer patients. Submit your abstract for ESMO Sarcoma and Rare Cancers 2025 by 7 Jan & join the conversation! #ESMORareCancers25 🔗 ow.ly/bxph50Ua6zJ

📖 To mark the 35th anniversary of Annals of Oncology, Prof. Cavalli, founding Editor-in-Chief (1989-2000), reflects on the journal’s origins, challenges, and its impact on advancing oncology. #ESMO 🔗 ow.ly/uC6R50UbLJE

📖 Have you read "Exosome-based liquid biopsies in cancer: opportunities and challenges", one of Annals of Oncology’s top-cited papers of 2023? #CancerResearch #AnnalsOfOncology 🔗 ow.ly/9AYe50U7MNP

📖 To mark 35 years of Annals of Oncology, putting a 2023 top-cited paper in the spotlight: "High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types." #AnnalsOfOncology 🔗 ow.ly/pbE650U7MPt

Congratulations to IOTECH Editor in Chief Prof John Haanen on receiving the 2024 KNAW Bob Pinedo Cancer Care Award. www.esmoiotech.org #ESMO

#ESMOImmuno24: 🚨 Last Chance to Save on Registration 🚨 Exciting times ahead! Late-breaking abstract authors-titles are now online! 👉 Head to the programme to see the science you can look forward to and register today! Hope to see you there! 🔗https://ow.ly/QvNu50U483r

👉 Discover how to implement the ESMO Guidelines in real-world clinical scenarios and contribute to a richer learning experience by submitting your questions to the experts. 🔗 ow.ly/3v8h50U67lG

Annals of Oncology received its first impact factor in 1994, a key achievement in #oncology publishing. 3 decades later the IF stands at 56.7, ranking 4th in oncology www.sciencedirect.com/journal/anna...